GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Metastatic, Prostate, Advanced, Cancer, GVAX, Vaccine
Eligibility Criteria
Inclusion Criteria: Histologically diagnosed adenocarcinoma of the prostate Progressive disease ECOG performance status of 0 or 1 Adequate bone marrow, renal and hepatic function Castrate levels of testosterone May have had local radiotherapy as part of their initial treatment or 28 days after palliative radiotherapy or one chemotherapy treatment for metastatic disease Exclusion Criteria: Transitional cell, small cell or squamous cell prostate cancer Systemic steroid therapy within 10-days of enrollment Documented history of active autoimmune disease such as lupus, sarcoidosis, rheumatoid arthritis, glomerulonephritis or vasculitis Clinically significant active infections History of other malignancies over past 5-years (except non-melanoma skin cancer or controlled superficial bladder cancer) Uncontrolled medical problems (i.e. neurological, cardiovascular) considered high risk for investigational new drug treatment Prior treatment with an investigational drug within 30-days of study entry Seropositive for HIV, hepatitis B surface antigen or hepatitis C
Sites / Locations
- Providence Portland Medical Center